Highly Sensitive Single Domain Antibody–Quantum Dot Conjugates for Detection of HER2 Biomarker in Lung and Breast Cancer Cells

ACS Nano ◽  
2014 ◽  
Vol 8 (6) ◽  
pp. 5682-5695 ◽  
Author(s):  
Tatsiana Y. Rakovich ◽  
Omar K. Mahfoud ◽  
Bashir M. Mohamed ◽  
Adriele Prina-Mello ◽  
Kieran Crosbie-Staunton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantum Dot ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Single Domain ◽  
Single Domain Antibody ◽  
Domain Antibody ◽  
Highly Sensitive

scholarly journals Production and comparison of mature single-domain ‘trefoil’ peptides pNR-2/pS2 Cys58 and pNR-2/pS2 Ser58

1995 ◽  
Vol 308 (3) ◽  
pp. 1001-1007 ◽  
Author(s):  
M P Chadwick ◽  
F E B May ◽  
B R Westley
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Gel Filtration ◽  
Thiol Group ◽  
Cysteine Residue ◽  
Exchange Chromatography ◽  
Single Domain ◽  
Trefoil Peptides ◽  
Trefoil Peptide

The preparation and purification of recombinant mature pNR-2/pS2, a single-domain member of the ‘trefoil’ family of cysteine-rich secreted proteins, is described. Analysis of recombinant pNR-2/pS2 by ion-exchange chromatography showed that it was heterogeneous. The heterogeneity was reduced by treatment with thiol-group-containing reagents, suggesting that it is caused by the odd number of cysteine residues in mature pNR-2/pS2, and this view was reinforced by mutation of the extra-trefoil domain cysteine residue, Cys58, to a serine residue. Electrophoresis of recombinant pNR-2/pS2 Cys58 and pNR-2/pS2 Ser58 proteins under non-denaturing conditions confirmed that the Ser58 mutant is much more homogeneous, and showed that most of pNR-2/pS2 Ser58 co-migrates as a single band with pNR-2/pS2 secreted from breast-cancer cells in culture. Treatment of recombinant pNR-2/pS2 proteins with various thiol-group-reactive reagents indicated that cysteine is the most effective at producing recombinant pNR-2/pS2 that co-migrates with pNR-2/pS2 secreted by breast-cancer cells. Dithiothreitol appeared to denature the proteins, and GSH was relatively ineffective. pNR-2/pS2 Cys58 treated with cysteine and untreated pNR-2/pS2 Ser58 had the same apparent molecular mass, measured by gel filtration, as pNR-2/pS2 secreted from breast-cancer cells. This is the first report of the production of a recombinant mature single-domain trefoil peptide and should greatly facilitate elucidation of the structure and function of pNR-2/pS2.

scholarly journals Highly sensitive optical detection of specific protein in breast cancer cells using microstructured fiber in extremely low sample volume

2010 ◽  
Vol 15 (1) ◽  
pp. 017005 ◽  
Author(s):  
Saraswathi Padmanabhan ◽  
Vengalathunadakal K. Shinoj ◽  
Vadakke M. Murukeshan ◽  
Parasuraman Padmanabhan
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Optical Detection ◽  
Specific Protein ◽  
Sample Volume ◽  
Microstructured Fiber ◽  
Highly Sensitive

scholarly journals Aptamer Embedded Arch-Cruciform DNA Assemblies on 2-D VS2 Scaffolds for Sensitive Detection of Breast Cancer Cells

Biosensors ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 378
Author(s):  
Jinfeng Quan ◽  
Yihan Wang ◽  
Jialei Zhang ◽  
Kejing Huang ◽  
Xuemei Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Dna Sequences ◽  
Breast Cancer Cells ◽  
Limit Of Detection ◽  
Sensitive Detection ◽  
Highly Sensitive ◽  
Highly Sensitive Detection ◽  
Cruciform Dna ◽  
Mcf 7

Arch-cruciform DNA are self-assembled on AuNPs/VS2 scaffold as a highly sensitive and selective electrochemical biosensor for michigan cancer foundation-7 (MCF-7) breast cancer cells. In the construction, arch DNA is formed using two single-strand DNA sequences embedded with the aptamer for MCF-7 cells. In the absence of MCF-7 cells, a cruciform DNA labeled with three terminal biotin is bound to the top of arch DNA, which further combines with streptavidin-labeled horseradish peroxidase (HRP) to catalyze the hydroquinone-H2O2 reaction on the electrode surface. The presence of MCF-7 cells can release the cruciform DNA and reduce the amount of immobilized HRP, thus effectively inhibiting enzyme-mediated electrocatalysis. The electrochemical response of the sensor is negatively correlated with the concentration of MCF-7 cells, with a linear range of 10 − 1 × 105 cells/mL, and a limit of detection as low as 5 cells/mL (S/N = 3). Through two-dimensional materials and enzyme-based dual signal amplification, this biosensor may pave new ways for the highly sensitive detection of tumor cells in real samples.

scholarly journals First-in-human Study of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer

2021 ◽  
Author(s):  
Lingzhou Zhao ◽  
Changcun Liu ◽  
Yan Xing ◽  
Jin He ◽  
Jim O’Doherty ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Radiation Dosimetry ◽  
Single Domain ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
Single Domain Antibody ◽  
Primary Tumors ◽  
Non Invasive ◽  
Domain Antibody

Abstract Background: Accurate determination of human epidermal growth factor receptor 2 (HER2) expression is essential for HER2-targeted therapy. HER2 expression in a complex environment, such as in a heterogenous tumor, makes precise assessment difficult using current methods. Therefore, we developed a novel 99mTc-labeled anti-HER2-single domain antibody (99mTc-NM-02) as a molecular imaging tracer for non-invasive detection of HER2 expression and investigated its safety, radiation dosimetry, biodistribution, and tumor-targeting potential in breast cancer patients.Methods: A lead compound (NM-02) was screened from a library of hexahistidine-tagged anti-HER2-single domain antibodies and labeled with 99mTc for the preparation of 99mTc-NM-02 tracer. Ten women with breast cancer were administered 99mTc-NM-02 at a mean dose of 458 ± 37 MBq (406−510 MBq), corresponding to 100 μg of NM-02. Whole-body and local SPECT/CT images were acquired at 1 and 2 h post-administration to investigate the tumor-targeting potential in primary and metastatic lesions. Additional images were acquired at 10 min, 3 h, and 24 h in three patients to calculate radiation dosimetry. Physical evaluation and blood analysis were performed for safety assessment.Results: No drug-related adverse reactions occurred. The tracer mainly accumulated in the kidneys and liver with mild uptake in the spleen, intestines, and thyroid, but only background levels were observed in other organs where primary tumors and metastases typically occurred. The mean effective dose was 6.56 × 10−3 mSv/MBq, and tracer uptake was visually observed in primary tumors and metastases. Owing to the fast clearance of the tracer, we were able to sufficiently discern uptake over normal background in both primary lesions and metastases within 2 h after injection. A maximal standard uptake value of 1.5 could be a reasonable cutoff for determining HER2 positivity using SPECT/CT imaging.Conclusions: Our 99mTc-NM-02 tracer can be safely used for imaging in breast cancer patients with reasonable radiation doses, favorable biodistribution and imaging characteristics. 99mTc-NM-02 SPECT imaging may provide an accurate and non-invasive method to detect HER2 status in breast cancer patients.Trial registration: ClinicalTrials.gov, NCT04040686. Registered 30 July 2019. https://clinicaltrials.gov/ct2/show/NCT04040686.

scholarly journals Targeting breast cancer cells with a CuInS2/ZnS quantum dot-labeled Ki-67 bioprobe

2017 ◽  
Author(s):  
Guang Sun ◽  
Wanying Xing ◽  
Ren Xing ◽  
Liu Cong ◽  
Sun Tong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantum Dot ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Ki 67
Sign in / Sign up

Export Citation Format

Share Document